Flow Cytometric Monitoring of Glycoprotein IIb/IIIa Blockade and Platelet Function in Patients With Acute Myocardial Infarction Receiving Reteplase, Abciximab, and Ticlopidine
- 26 September 2000
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 102 (13) , 1490-1496
- https://doi.org/10.1161/01.cir.102.13.1490
Abstract
Background—Improvement of thrombolysis may be achieved by concomitant strong platelet inhibition. To monitor platelet function in patients with myocardial infarction (n=46) who were treated with th...Keywords
This publication has 8 references indexed in Scilit:
- Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopeniaThe American Journal of Cardiology, 1999
- Platelet GPIIb-IIIa blockersThe Lancet, 1999
- Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIbβ3) InhibitorsBlood, 1998
- Effects of Reteplase and Alteplase on Platelet Aggregation and Major Receptor Expression During the First 24 Hours of Acute Myocardial Infarction TreatmentJournal of the American College of Cardiology, 1998
- Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.Journal of Clinical Investigation, 1997
- Abciximab (c7E3 Fab)Drugs, 1994
- Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIaBlood Coagulation & Fibrinolysis, 1993
- Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.Journal of Clinical Investigation, 1990